Recombinant Human Serpin E1/PAI-1 protein (rFc Tag)

种属

Human

纯度

>90 %, SDS-PAGE

标签

rFc Tag

生物活性

未测试

Cat no : Eg3798

Print datasheet

Synonyms

PAI-1, SERPINE1, SERPINE1, PAI-1, PAI, PAI 1



产品信息

纯度 >90 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Not tested
来源 HEK293-derived Human Serpin E1 protein Val24-Pro402 (Accession# P05121-1) with a rabbit IgG Fc tag at the N-terminus.
基因ID 5054
蛋白编号 P05121-1
预测分子量 70.0 kDa
SDS-PAGE 65-75 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

SERPINE1, also named as Plasminogen activator inhibitor type 1 (PAI-1), is a member of the serine protease inhibitor (SERPIN) superfamily. It is produced by the vascular endothelium, the liver, the monocytes/macrophagues, the platelets and the adipose tissue. High plasma levels of PAI-1 have been associated with an increased risk of suffering cardiovascular diseases. It is implicated in the pathogenesis of obesity, insulin resistance and type 2 diabetes. In several tumor types, SERPINE1 expression is up-regulated and it has been described as a poor prognostic marker. Besides its prognostic value, SERPINE1 expression has been validated as a marker for therapy decision making in patients with node-negative breast cancer. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia.

参考文献:

1. Huang J. et al.(2012). Blood. 20: 4873-81. 2. Kohler HP. et al. (2000). N Engl J Med. 342: 1792-801. 3. Festa A. et al. (2006). Circulation. 113: 1753-9. 4. Look MP. et al. (2002). J Natl Cancer Inst. 16;94(2):116-28. 5. Ulisse S. et al. (2009). Curr Cancer Drug Targets. 9(1):32-71.